Evidence map›Paper›PMID 27512103›Full record

Trial reportCirculation. Heart failure2016

Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).

Siu-Hin Wan, Susanna R Stevens, Barry A Borlaug, Kevin J Anstrom, Anita Deswal, G Michael Felker, Michael M Givertz, Bradley A Bart, W H Wilson Tang, Margaret M Redfield and 1 more

Registry-linked trialOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01132846 (Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01132846 phase2completednot on this map

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study

TypeinterventionalSponsorDuke UniversityRan2010 to 2013Enrolled360ConditionsAcute Heart FailureArmsPlacebo, Nesiritide, Dopamine
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Siu-Hin WanFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Susanna R StevensFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Barry A BorlaugFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Kevin J AnstromFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Anita DeswalFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
G Michael FelkerFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Michael M GivertzFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Bradley A BartFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
W H Wilson TangFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Margaret M RedfieldFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.).
Horng H ChenFrom the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (S.-H.W., B.A.B., M.M.R., H.H.C.); Duke Clinical Research Institute, Durham, NC (S.R.S., K.J.A.); Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX (A.D.); Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F.); Department of Medicine, Brigham and Women's Hospital, Boston, MA (M.M.G.); Hennepin County Medical Center and Hennepin Heart Center, Minneapolis, MN (B.A.B.); and Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.). chen.horng@mayo.edu.
Brigham and Women's Hospital · USClinical Research Institute · USDuke Medical Center · USHennepin County Medical Center · USMichael E. DeBakey VA Medical Center · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Heart Failure Clinical Research Network Coordinating CenterU10HL084904 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J, HERNANDEZ, ADRIAN · 2012 to 2018
$38.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Research Desogn and Biostatistics CoreU54MD007588 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI OFILI, ELIZABETH O. · 2012 to 2018
$24.8M
Recruitment and Phenotyping CoreP01HL076611 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2005 to 2015
$19.6M
Human Cardiorenal SyndromeR01HL084155 · NHLBI · MAYO CLINIC ROCHESTER · PI HORNG H CHEN · 2009 to 2026
$5.5M
Mayo Heart Failure Regional Clinical CenterU10HL110262 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2018
$3.6M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
SALsalate to Improve Exercise toleraNce and LVDD in T2dm-DHF (SALIENT-DHF trial)U10HL110309 · NHLBI · WASHINGTON UNIVERSITY · PI DAVILA-ROMAN, VICTOR G., MANN, DOUGLAS L · 2012 to 2018
$3.5M
Harvard Regional Clinical Center of the NHLBI Heart Failure NetworkU10HL110337 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GIVERTZ, MICHAEL M, LEWIS, GREGORY DYER · 2012 to 2018
$3.5M
NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000454NCRR NIH HHS UL1 RR025008NHLBI NIH HHS P01 HL076611NHLBI NIH HHS R01 HL084155NHLBI NIH HHS U01 HL084861NHLBI NIH HHS U01 HL084889NHLBI NIH HHS U01 HL084890NHLBI NIH HHS U01 HL084891NHLBI NIH HHS U01 HL084907NHLBI NIH HHS U01 HL084931NHLBI NIH HHS U10 HL084904NHLBI NIH HHS U10 HL110262NHLBI NIH HHS U10 HL110297NHLBI NIH HHS U10 HL110302NHLBI NIH HHS U10 HL110309NHLBI NIH HHS U10 HL110312NHLBI NIH HHS U10 HL110336NHLBI NIH HHS U10 HL110337NHLBI NIH HHS U10 HL110338NIMHD NIH HHS U54 MD007588
6 · The paper itself

Abstract

backgroundThe ROSE AHF trial (Renal Optimization Strategies Evaluation in Acute Heart Failure) found that when compared with placebo, neither low-dose dopamine (2 µg/kg per minute) nor low-dose nesiritide (0.005 μg/kg per minute without bolus) enhanced decongestion or preserved renal function in AHF patients with renal dysfunction. However, there may be differential responses to vasoactive agents in AHF patients with reduced versus preserved ejection fraction (EF). This post hoc analysis examined potential interaction between treatment effect and EF (EF ≤40% versus >40%) on the ROSE AHF end points. METHODS AND

resultsROSE AHF enrolled AHF patients (n=360; any EF) with renal dysfunction. The coprimary end points were cumulative urine volume and the change in serum cystatin-C in 72 hours. The effect of dopamine (interaction P=0.001) and nesiritide (interaction P=0.039) on urine volume varied by EF group. In heart failure with reduced EF, urine volume was higher with active treatment versus placebo, whereas in heart failure with preserved EF, urine volume was lower with active treatment. The effect of dopamine and nesiritide on weight change, sodium excretion, and incidence of AHF treatment failure also varied by EF group (interaction P<0.05 for all). There was no interaction between vasoactive treatment's effect and EF on change in cystatin-C. Compared with placebo, dopamine was associated with improved clinical outcomes in heart failure with reduced EF and worse clinical outcomes in heart failure with preserved EF. With nesiritide, there were no differences in clinical outcomes when compared with placebo in both heart failure with reduced EF and heart failure with preserved EF.

conclusionsIn this post hoc analysis of ROSE AHF, the response to vasoactive therapies differed in patients with heart failure with reduced EF and heart failure with preserved EF. Investigations of AHF therapies should assess the potential for differential responses in AHF with preserved versus reduced EF. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01132846.

Indexed as

AgedBiomarkersCardiotonic AgentsCystatin CDiureticsDopamineDouble-Blind MethodFemaleGlomerular Filtration RateHeart FailureHumansKidneyKidney DiseasesMaleMiddle AgedNatriuretic Peptide, BrainBiomarkersCardiotonic AgentsCST3 protein, humanCystatin CDiureticsDopamineNatriuretic Peptide, Braindopamineheart failurehumansincidencekidneynatriuretic peptide, brain

Identifiers

PMID27512103
PMCPMC5034712
OpenAlexW2481849208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.